David Peritt
Company: Lupagen Inc.
Job title: Founder & Chief Scientific Officer
Seminars:
Translating Cell Therapy from Ex Vivo to In Vivo: Opportunities and Challenges 9:00 am
The massive success of CAR-T therapies for treating haematological cancers have been limited by huge challenges including long manufacturing timelines, and hence resulting in expensive production costs. It is important to assess the advantages an in vivo engineering approach can bring to the cell therapy space over traditional autologous/allogeneic approaches, to become a front line,…Read more
day: Pre-Conference Workshop Day
Industry Leader’s Fireside Chat: Comparing Different Delivery Constructs to Pave the Future of Cell Therapy 8:45 am
An executive panel discussion from the industry leaders of the field to set the scene on the future of In Vivo approaches within the cell therapy space. Ask your questions live to understand the expert’s thoughts on key topics including: • Reviewing different platform technologies for reprogramming in-vivo human cells and tissues e.g LNP versus…Read more
day: Day 1
Extracorporeal Gene Delivery for in situ Targeting of Immune Cells 11:30 am
Bedside procedure increases dose control, safety and limits off target impact Enabling redosing by lowering immunogenicity to vehicle increases efficacy and enables use of RNARead more
day: Day 1
Chair’s Opening Remarks 8:30 am
day: Day 1